Bone diseases: Romosozumab — on track or derailed?

Nature Reviews Endocrinology, Published online: 13 October 2017; doi:10.1038/nrendo.2017.136

Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag regarding possible adverse cardiovascular events derail this promising new drug for osteoporosis?

中文翻译：

---

骨疾病：Romosozumab-在轨道上还是出轨？

骨疾病：Romosozumab-是否在轨道上或出轨？

Nature Reviews Endocrinology，在线发表：2017年10月13日；doi：10.1038 / nrendo.2017.136

Romosozumab是一种新近开发的硬化素抑制剂，可刺激骨形成并抑制骨吸收，从而显着增加骨量并降低骨折风险。但是关于可能的不良心血管事件的危险信号会否使这种有前途的骨质疏松新药脱轨？